Aldosterone Synthase Inhibitors Market, By Drug Type (Selective Aldosterone Synthase Inhibitors, and Non-Selective CYP11B Inhibitors), By Drug (Osilodrostat, Lorundrostat, Baxdrostat, Vicadrostat, and Dexfadrostat), By Indication (Cushing’s Syndrome, Hypertension, and Primary aldosteronism (Conn\'s syndrome) , Heart Failure (Heart Failure with Reduced Ejection Fraction (HFrEF), Heart Failure with Preserved Ejection Fraction (HFpEF)), and Metastatic Hormone-sensitive Prostate Cancer (mHSPC)), By Stage of Development (Preclinical, Phase I Clinical Trials, Phase II Clinical Trials, Phase III Clinical Trials, and Approved or Marketed), By Gender (Male, and Female), By End User (Hospitals, Cardiology Clinics, Nephrology Clinics, Research and Academic Institutes, and Contract Research Organizations (CROs)), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)